NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited tre...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. An on-demand webc...
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patient lives, today announced the expansion of its global LungFit® PH distribution network. The Company has recentl...
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems in its network Reaffirm revenue guidance of $12-$16 million for the full fiscal year 2026 Conference call at 4:30 p.m. ET today, August 12th GARDEN CITY, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAI...
Moody's Ratings (Moody's) assigned a Ba1 rating to Ball Corporation's ("Ball Corp.") senior unsecured notes due 2033. The company's Ba1 corporate family rating (CFR), Ba1-PD probability of default rating (PDR), SGL-2 speculative grade liquidity rating (SGL) and other existing ratings are unchanged. ...
BCB Bancorp, Inc. Earns $3.6 Million in Second Quarter 2025; Reports $0.18 EPS and Declares Quarterly Cash Dividend of $0.16 Per Share BAYONNE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported net income of $3.6 million for the second quarter of 2025, compared to a net loss of $8.3 million in the first quarter of 2025, and net income of $2.8 million for the second quarter of 2024. Earnings per diluted share for the second quarter was $0.18 compared to a loss of ($0.51) per dil...
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern T...
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc. GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the...
BCB Bank announces Daniel A. Araujo’s promotion to Senior Vice President and Chief Lending Officer BAYONNE, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- BCB Bank is proud to announce the promotion of Daniel A. Araujo to Senior Vice President and Chief Lending Officer. This promotion is in alignment with BCB’s customer-first approach and dedication to organizational excellence. Mr. Araujo brings more than 20 years of industry knowledge and lending management experience to the Bank. Araujo is a highly respected industry veteran who brings a wealth of experience and an entrepreneurial mindset to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.